On this page
temazepam
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Benzodiazepine [EPC] | EPC | All 48 members |
| Benzodiazepines [CS] | CS | All 48 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 071457-001 | TEMAZEPAM | CAPSULE | TEMAZEPAM | Prescription | AB | ||
| 071457-002 | TEMAZEPAM | CAPSULE | TEMAZEPAM | Prescription | AB | ||
| 071457-003 | TEMAZEPAM | CAPSULE | TEMAZEPAM | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 19 | Labeling | Approved | August 19, 2024 | Standard |
| Supplement | 17 | Labeling | Approved | August 3, 2022 | Standard |
| Supplement | 14 | Labeling | Approved | August 27, 2019 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | June 22, 2012 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | June 22, 2012 | — |
| Supplement | 9 | Labeling | Approved | April 17, 2012 | — |
| Supplement | 6 | Labeling | Approved | July 7, 2004 | — |
| Supplement | 5 | Labeling | Approved | December 28, 1993 | — |
| Supplement | 4 | Labeling | Approved | February 4, 1991 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | July 31, 1989 | — |
| Supplement | 21 | Labeling | Approved | June 12, 1989 | — |
| Supplement | 3 | Labeling | Approved | June 12, 1989 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | November 4, 1987 | — |
| Original application | 1 | Approved | April 21, 1987 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251008). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingWARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation ( see WARNINGS and PRECAUTIONS) . • The use of benzodiazepines, including temazepam capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing temazepam capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction ( see WARNINGS). • The continued use of benzodiazepines, including temazepam capsules, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of temazepam capsules after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam capsules or reduce the dosage ( see DOSAGE AND ADMINISTRATION and WARNINGS).
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules, USP should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined. Discontinuation or Dosage Reduction of Temazepam Capsules To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam capsules or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly ( see WARNINGS, Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence ).
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Benzodiazepines may cause fetal harm when administered to a pregnant woman. An increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. Transplacental distribution has resulted in neonatal CNS depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. Reproduction studies in animals with temazepam were performed in rats and rabbits. In a perinatal-postnatal study in rats, oral doses of 60 mg/kg/day resulted in increasing nursling mortality. Teratology studies in rats demonstrated increased fetal resorptions at doses of 30 and 120 mg/kg in one study and increased occurrence of rudimentary ribs, which are considered skeletal variants, in a second study at doses of 240 mg/kg or higher. In rabbits, occasional abnormalities such as exencephaly and fusion or asymmetry of ribs were reported without dose relationship. Although these abnormalities were not found in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg or higher, there was an increased incidence of the 13th rib variant when compared to the incidence in concurrent and historical controls. Temazepam capsules are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should be instructed to discontinue the drug prior to becoming pregnant. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered.
Warnings and Cautions
openFDA Drug LabelingWarnings and Precautions Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including Temazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug related mortality compared to use of opioids alone. If a decision is made to prescribe Temazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Temazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking Temazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when Temazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS, DRUG INTERACTIONS). Abuse, Misuse, and Addiction The use of benzodiazepines, including temazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE, Abuse). Before prescribing temazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of temazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of temazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam or reduce the dosage (a patient-specific plan should be used to taper the dose) (see DOSAGE AND ADMINISTRATION, Discontinuation or Dosage Reduction of temazepam). Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including temazepam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of temazepam after continued use , or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see DRUG ABUSE AND DEPENDENCE, Dependence). Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see DRUG ABUSE AND DEPENDENCE, Dependence). Sleep disturbance may be the presenting manifestation of an underlying physical and/or psychiatric disorder. Consequently, a de …
Warnings
openFDA Drug LabelingWARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including temazepam capsules, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe temazepam capsules concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of temazepam capsules than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking temazepam capsules, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the risks of respiratory depression and sedation when temazepam capsules are used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined ( see PRECAUTIONS, Drug Interactions ). Abuse, Misuse, and Addiction The use of benzodiazepines, including temazepam capsules, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death ( see DRUG ABUSE AND DEPENDENCE, Abuse ). Before prescribing temazepam capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of temazepam capsules, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of temazepam capsules along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam capsules or reduce the dosage (a patient-specific plan should be used to taper the dose) ( see DOSAGE AND ADMINISTRATION, Discontinuation or Dosage Reduction of Temazepam Capsules ). Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including temazepam capsules, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of temazepam capsules after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) ( see DRUG ABUSE AND DEPENDENCE, Dependence ). Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months ( see DRUG ABUSE AND DEPENDENCE, Dependence ). Sleep disturbanc …
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS During controlled clinical studies in which 1076 patients received temazepam at bedtime, the drug was well tolerated. Side effects were usually mild and transient. Adverse reactions occurring in 1% or more of patients are presented in the following table: Temazepam Placebo % Incidence (n=1076) % Incidence (n=783) Drowsiness 9.1 5.6 Headache 8.5 9.1 Fatigue 4.8 4.7 Nervousness 4.6 8.2 Lethargy 4.5 3.4 Dizziness 4.5 3.3 Nausea 3.1 3.8 Hangover 2.5 1.1 Anxiety 2.0 1.5 Depression 1.7 1.8 Dry Mouth 1.7 2.2 Diarrhea 1.7 1.1 Abdominal Discomfort 1.5 1.9 Euphoria 1.5 0.4 Weakness 1.4 0.9 Confusion 1.3 0.5 Blurred Vision 1.3 1.3 Nightmares 1.2 1.7 Vertigo 1.2 0.8 The following adverse events have been reported less frequently (0.5% to 0.9%): Central Nervous System – anorexia, ataxia, equilibrium loss, tremor, increased dreaming Cardiovascular – dyspnea, palpitations Gastrointestinal – vomiting Musculoskeletal – backache Special Senses – hyperhidrosis, burning eyes Amnesia, hallucinations, horizontal nystagmus, and paradoxical reactions including restlessness, overstimulation and agitation were rare (less than 0.5%). To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-432-8534 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Drug Interactions
openFDA Drug LabelingDrug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. The pharmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling.
Description
openFDA Drug LabelingDESCRIPTION Temazepam is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2 H -1,4-benzodiazepin-2-one, and the structural formula is: C 16 H 13 CIN 2 O 2 MW = 300.74 Temazepam is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol USP. Temazepam Capsules, USP, 7.5 mg, 15 mg, 22.5 mg and 30 mg, are for oral administration. 7.5 mg, 15 mg, 22.5 mg and 30 mg Capsules Active Ingredient: temazepam USP 7.5 mg Capsules Inactive Ingredients: Corn starch, lactose anhydrous, magnesium stearate, sodium lauryl sulfate, FD&C Red #40 and titanium dioxide. May also include: sodium lauryl sulfate. Imprinting ink may contain ammonium hydroxide, ethanol, isopropyl alcohol, butanol, shellac, potassium hydroxide, propylene glycol, and black iron oxide. 15 mg Capsules Inactive Ingredients: Corn starch, lactose anhydrous, magnesium stearate, sodium lauryl sulfate, FD&C Blue #1, FD&C yellow # 6, gelatin and titanium dioxide. May also include: sodium lauryl sulfate. Imprinting ink may contain ammonium hydroxide, ethanol, isopropyl alcohol, butanol, shellac, potassium hydroxide, propylene glycol, and black iron oxide. 22.5 mg Capsules Inactive Ingredients: Corn starch, lactose anhydrous, magnesium stearate, sodium lauryl sulfate, FD&C Blue #1, FD&C Red #40, gelatin and titanium dioxide. May also include: sodium lauryl sulfate. Imprinting ink may contain ammonium hydroxide, ethanol, isopropyl alcohol, butanol, shellac, potassium hydroxide, propylene glycol, and black iron oxide. 30 mg Capsules Inactive Ingredients: Corn starch, lactose anhydrous, magnesium stearate, sodium lauryl sulfate, gelatin and titanium dioxide. May also include: sodium lauryl sulfate. Imprinting ink may contain ammonium hydroxide, ethanol, isopropyl alcohol, butanol, shellac, potassium hydroxide, propylene glycol, and black iron oxide. Structural Formula
Overdosage
openFDA Drug LabelingOVERDOSAGE Manifestations of acute overdosage of temazepam capsules can be expected to reflect the CNS effects of the drug and include somnolence, confusion, and coma, with reduced or absent reflexes, respiratory depression, and hypotension. The oral LD 50 of temazepam capsules were 1963 mg/kg in mice, 1833 mg/kg in rats, and >2400 mg/kg in rabbits. Treatment If the patient is conscious, vomiting should be induced mechanically or with emetics. Gastric lavage should be employed utilizing concurrently a cuffed endotracheal tube if the patient is unconscious to prevent aspiration and pulmonary complications. Maintenance of adequate pulmonary ventilation is essential. The use of pressor agents intravenously may be necessary to combat hypotension. Fluids should be administered intravenously to encourage diuresis. The value of dialysis has not been determined. If excitation occurs, barbiturates should not be used. It should be borne in mind that multiple agents may have been ingested. Flumazenil (Romazicon ® ) * , a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS should be consulted prior to use. Up-to-date information about the treatment of overdose can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians' Desk Reference ®** .
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Temazepam Capsules USP 7.5 mg Pink opaque cap and white opaque body, imprinted “7.5 mg” on cap and “Novel 120” on the body in black ink. Bottle of 30 NDC 76420-472-30 (repackaged/relabeled from NDC 67877-148-30) Bottle of 60 NDC 76420-472-60 (repackaged from NDC 67877-148-XX) Bottle of 90 NDC 76420-472-90 (repackaged from NDC 67877-148-XX) Bottle of 100 NDC 76420-472-01 (relabeled from NDC 67877-148-01) Bottle of 500 NDC 76420-472-05 (relabeled from NDC 67877-148-05) 15 mg Blue opaque cap and white opaque body, imprinted “15 mg” on cap and “Novel 121” on the body in black ink. Bottle of 30 NDC 76420-473-30 (repackaged from NDC 67877-146-XX) Bottle of 60 NDC 76420-473-60 (repackaged from NDC 67877-146-XX) Bottle of 90 NDC 76420-473-90 (repackaged from NDC 67877-146-XX) Bottle of 100 NDC 76420-473-01 (relabeled from NDC 67877-146-01) Bottle of 500 NDC 76420-473-05 (relabeled from NDC 67877-146-05) 22.5 mg Light blue opaque cap and white opaque body, imprinted “22.5 mg” on cap and “Novel 122” on the body in black ink. Bottle of 30 NDC 76420-474-30 (relabeled from NDC 67877-149-30) Bottle of 60 NDC 76420-474-60 (repackaged from NDC 67877-149-XX) Bottle of 90 NDC 76420-474-90 (repackaged from NDC 67877-149-XX) Bottle of 100 NDC 76420-474-01 (relabeled from NDC 67877-149-01) Bottle of 500 NDC 76420-474-05 (relabeled from NDC 67877-149-05) 30 mg White opaque cap and body, imprinted “30 mg” on cap and “Novel 123” on the body in black ink. Bottle of 30 NDC 76420-475-30 (repackaged from NDC 67877-147-XX) Bottle of 60 NDC 76420-475-60 (repackaged from NDC 67877-147-XX) Bottle of 90 NDC 76420-475-90 (repackaged from NDC 67877-147-XX) Bottle of 100 NDC 76420-475-01 (relabeled from NDC 67877-147-01) Bottle of 500 NDC 76420-475-05 (relabeled from NDC 67877-147-05) Dispense in a well-closed, light-resistant container with a child-resistant closure. Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Relabeled and Repackaged by: Enovachem PHARMACEUTICALS Torrance, CA 90501
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TEMAZEPAM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0186-0 | 50090-0186 | A-S Medication Solutions | 30 CAPSULE in 1 BOTTLE (50090-0186-0) | November 28, 2014 |
| 50090-0285-1 | 50090-0285 | A-S Medication Solutions | 30 CAPSULE in 1 BOTTLE (50090-0285-1) | November 28, 2014 |
| 0228-2076-10 | 0228-2076 | Actavis Pharma, Inc. | 100 CAPSULE in 1 BOTTLE (0228-2076-10) | September 30, 1990 |
| 0228-2076-50 | 0228-2076 | Actavis Pharma, Inc. | 500 CAPSULE in 1 BOTTLE (0228-2076-50) | September 30, 1990 |
| 0228-2077-10 | 0228-2077 | Actavis Pharma, Inc. | 100 CAPSULE in 1 BOTTLE (0228-2077-10) | September 30, 1990 |
| 0228-2077-50 | 0228-2077 | Actavis Pharma, Inc. | 500 CAPSULE in 1 BOTTLE (0228-2077-50) | September 30, 1990 |
| 80425-0191-1 | 80425-0191 | Advanced Rx Pharmacy of Tennessee, LLC | 20 CAPSULE in 1 BOTTLE (80425-0191-1) | February 17, 2024 |
| 80425-0191-2 | 80425-0191 | Advanced Rx Pharmacy of Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (80425-0191-2) | March 30, 2023 |
| 80425-0295-1 | 80425-0295 | Advanced Rx Pharmacy of Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (80425-0295-1) | April 4, 2023 |
| 80425-0295-2 | 80425-0295 | Advanced Rx Pharmacy of Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (80425-0295-2) | April 4, 2023 |
| 80425-0295-3 | 80425-0295 | Advanced Rx Pharmacy of Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (80425-0295-3) | April 4, 2023 |
| 62332-379-30 | 62332-379 | Alembic Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (62332-379-30) | November 27, 2018 |
| 62332-379-31 | 62332-379 | Alembic Pharmaceuticals Inc. | 100 CAPSULE in 1 BOTTLE (62332-379-31) | November 27, 2018 |
| 62332-380-30 | 62332-380 | Alembic Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (62332-380-30) | November 27, 2018 |
| 62332-380-31 | 62332-380 | Alembic Pharmaceuticals Inc. | 100 CAPSULE in 1 BOTTLE (62332-380-31) | November 27, 2018 |
| 62332-380-71 | 62332-380 | Alembic Pharmaceuticals Inc. | 500 CAPSULE in 1 BOTTLE (62332-380-71) | November 27, 2018 |
| 62332-380-90 | 62332-380 | Alembic Pharmaceuticals Inc. | 90 CAPSULE in 1 BOTTLE (62332-380-90) | November 27, 2018 |
| 62332-381-30 | 62332-381 | Alembic Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (62332-381-30) | November 27, 2018 |
| 62332-382-30 | 62332-382 | Alembic Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (62332-382-30) | November 27, 2018 |
| 62332-382-31 | 62332-382 | Alembic Pharmaceuticals Inc. | 100 CAPSULE in 1 BOTTLE (62332-382-31) | November 27, 2018 |
| 62332-382-71 | 62332-382 | Alembic Pharmaceuticals Inc. | 500 CAPSULE in 1 BOTTLE (62332-382-71) | November 27, 2018 |
| 62332-382-90 | 62332-382 | Alembic Pharmaceuticals Inc. | 90 CAPSULE in 1 BOTTLE (62332-382-90) | November 27, 2018 |
| 46708-379-30 | 46708-379 | Alembic Pharmaceuticals Limited | 30 CAPSULE in 1 BOTTLE (46708-379-30) | November 27, 2018 |
| 46708-379-31 | 46708-379 | Alembic Pharmaceuticals Limited | 100 CAPSULE in 1 BOTTLE (46708-379-31) | November 27, 2018 |
| 46708-380-30 | 46708-380 | Alembic Pharmaceuticals Limited | 30 CAPSULE in 1 BOTTLE (46708-380-30) | November 27, 2018 |
| 46708-380-31 | 46708-380 | Alembic Pharmaceuticals Limited | 100 CAPSULE in 1 BOTTLE (46708-380-31) | November 27, 2018 |
| 46708-380-71 | 46708-380 | Alembic Pharmaceuticals Limited | 500 CAPSULE in 1 BOTTLE (46708-380-71) | November 27, 2018 |
| 46708-380-90 | 46708-380 | Alembic Pharmaceuticals Limited | 90 CAPSULE in 1 BOTTLE (46708-380-90) | November 27, 2018 |
| 46708-381-30 | 46708-381 | Alembic Pharmaceuticals Limited | 30 CAPSULE in 1 BOTTLE (46708-381-30) | November 27, 2018 |
| 46708-382-30 | 46708-382 | Alembic Pharmaceuticals Limited | 30 CAPSULE in 1 BOTTLE (46708-382-30) | November 27, 2018 |
| 46708-382-31 | 46708-382 | Alembic Pharmaceuticals Limited | 100 CAPSULE in 1 BOTTLE (46708-382-31) | November 27, 2018 |
| 46708-382-71 | 46708-382 | Alembic Pharmaceuticals Limited | 500 CAPSULE in 1 BOTTLE (46708-382-71) | November 27, 2018 |
| 46708-382-90 | 46708-382 | Alembic Pharmaceuticals Limited | 90 CAPSULE in 1 BOTTLE (46708-382-90) | November 27, 2018 |
| 68084-549-21 | 68084-549 | American Health Packaging | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-549-21) / 1 CAPSULE in 1 BLISTER PACK (68084-549-11) | August 1, 2012 |
| 65162-556-03 | 65162-556 | Amneal Pharmaceuticals LLC | 30 CAPSULE in 1 BOTTLE (65162-556-03) | May 23, 2016 |
| 65162-556-10 | 65162-556 | Amneal Pharmaceuticals LLC | 100 CAPSULE in 1 BOTTLE (65162-556-10) | May 23, 2016 |
| 65162-556-11 | 65162-556 | Amneal Pharmaceuticals LLC | 1000 CAPSULE in 1 BOTTLE (65162-556-11) | May 23, 2016 |
| 65162-556-50 | 65162-556 | Amneal Pharmaceuticals LLC | 500 CAPSULE in 1 BOTTLE (65162-556-50) | May 23, 2016 |
| 65162-557-03 | 65162-557 | Amneal Pharmaceuticals LLC | 30 CAPSULE in 1 BOTTLE (65162-557-03) | May 23, 2016 |
| 65162-557-10 | 65162-557 | Amneal Pharmaceuticals LLC | 100 CAPSULE in 1 BOTTLE (65162-557-10) | May 23, 2016 |
| 65162-557-11 | 65162-557 | Amneal Pharmaceuticals LLC | 1000 CAPSULE in 1 BOTTLE (65162-557-11) | May 23, 2016 |
| 65162-557-50 | 65162-557 | Amneal Pharmaceuticals LLC | 500 CAPSULE in 1 BOTTLE (65162-557-50) | May 23, 2016 |
| 65162-583-03 | 65162-583 | Amneal Pharmaceuticals LLC | 30 CAPSULE in 1 BOTTLE (65162-583-03) | May 23, 2016 |
| 65162-583-10 | 65162-583 | Amneal Pharmaceuticals LLC | 100 CAPSULE in 1 BOTTLE (65162-583-10) | May 23, 2016 |
| 65162-583-11 | 65162-583 | Amneal Pharmaceuticals LLC | 1000 CAPSULE in 1 BOTTLE (65162-583-11) | May 23, 2016 |
| 65162-583-50 | 65162-583 | Amneal Pharmaceuticals LLC | 500 CAPSULE in 1 BOTTLE (65162-583-50) | May 23, 2016 |
| 65162-584-03 | 65162-584 | Amneal Pharmaceuticals LLC | 30 CAPSULE in 1 BOTTLE (65162-584-03) | May 23, 2016 |
| 65162-584-10 | 65162-584 | Amneal Pharmaceuticals LLC | 100 CAPSULE in 1 BOTTLE (65162-584-10) | May 23, 2016 |
| 65162-584-11 | 65162-584 | Amneal Pharmaceuticals LLC | 1000 CAPSULE in 1 BOTTLE (65162-584-11) | May 23, 2016 |
| 65162-584-50 | 65162-584 | Amneal Pharmaceuticals LLC | 500 CAPSULE in 1 BOTTLE (65162-584-50) | May 23, 2016 |
| 53746-556-01 | 53746-556 | Amneal Pharmaceuticals of New York LLC | 100 CAPSULE in 1 BOTTLE (53746-556-01) | February 19, 2024 |
| 53746-556-05 | 53746-556 | Amneal Pharmaceuticals of New York LLC | 500 CAPSULE in 1 BOTTLE (53746-556-05) | February 19, 2024 |
| 53746-557-01 | 53746-557 | Amneal Pharmaceuticals of New York LLC | 100 CAPSULE in 1 BOTTLE (53746-557-01) | February 19, 2024 |
| 53746-557-05 | 53746-557 | Amneal Pharmaceuticals of New York LLC | 500 CAPSULE in 1 BOTTLE (53746-557-05) | February 19, 2024 |
| 43353-260-15 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 15 CAPSULE in 1 BOTTLE (43353-260-15) | November 18, 2016 |
| 43353-260-20 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 20 CAPSULE in 1 BOTTLE (43353-260-20) | December 28, 2018 |
| 43353-260-28 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE (43353-260-28) | July 18, 2018 |
| 43353-260-30 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (43353-260-30) | May 1, 2017 |
| 43353-260-53 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (43353-260-53) | November 18, 2016 |
| 43353-260-60 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (43353-260-60) | October 25, 2017 |
| 43353-312-10 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 10 CAPSULE in 1 BOTTLE (43353-312-10) | June 27, 2018 |
| 43353-312-15 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 15 CAPSULE in 1 BOTTLE (43353-312-15) | September 21, 2017 |
| 43353-312-28 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE (43353-312-28) | June 27, 2018 |
| 43353-312-30 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (43353-312-30) | May 1, 2017 |
| 43353-312-45 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 45 CAPSULE in 1 BOTTLE (43353-312-45) | September 21, 2017 |
| 43353-312-53 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (43353-312-53) | May 1, 2017 |
| 43353-312-60 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (43353-312-60) | May 1, 2017 |
| 67544-136-10 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 10 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-10) | August 26, 2004 |
| 67544-136-14 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 14 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-14) | August 26, 2004 |
| 67544-136-15 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 15 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-15) | September 16, 2004 |
| 67544-136-20 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 20 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-20) | September 1, 2004 |
| 67544-136-28 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-28) | August 30, 2009 |
| 67544-136-30 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-30) | October 16, 2004 |
| 67544-136-45 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 45 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-45) | September 1, 2004 |
| 67544-136-53 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-53) | October 16, 2004 |
| 67544-136-60 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE, PLASTIC (67544-136-60) | December 8, 2004 |
| 71610-004-30 | 71610-004 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (71610-004-30) | August 14, 2017 |
| 71610-004-53 | 71610-004 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (71610-004-53) | November 22, 2017 |
| 71610-004-60 | 71610-004 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (71610-004-60) | November 22, 2017 |
| 71610-625-10 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 10 CAPSULE in 1 BOTTLE (71610-625-10) | June 14, 2024 |
| 71610-625-15 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 15 CAPSULE in 1 BOTTLE (71610-625-15) | December 10, 2021 |
| 71610-625-20 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 20 CAPSULE in 1 BOTTLE (71610-625-20) | June 14, 2024 |
| 71610-625-28 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE (71610-625-28) | June 14, 2024 |
| 71610-625-30 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (71610-625-30) | December 10, 2021 |
| 71610-625-45 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 45 CAPSULE in 1 BOTTLE (71610-625-45) | December 10, 2021 |
| 71610-625-53 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (71610-625-53) | December 10, 2021 |
| 71610-625-60 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (71610-625-60) | December 10, 2021 |
| 71610-626-15 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | 15 CAPSULE in 1 BOTTLE (71610-626-15) | December 10, 2021 |
| 71610-626-28 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE (71610-626-28) | March 7, 2024 |
| 71610-626-30 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (71610-626-30) | December 10, 2021 |
| 71610-626-53 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | 60 CAPSULE in 1 BOTTLE (71610-626-53) | December 10, 2021 |
| 71610-626-60 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (71610-626-60) | February 29, 2024 |
| 71610-986-28 | 71610-986 | Aphena Pharma Solutions - Tennessee, LLC | 28 CAPSULE in 1 BOTTLE (71610-986-28) | February 9, 2026 |
| 71610-986-30 | 71610-986 | Aphena Pharma Solutions - Tennessee, LLC | 30 CAPSULE in 1 BOTTLE (71610-986-30) | February 9, 2026 |
| 71610-986-60 | 71610-986 | Aphena Pharma Solutions - Tennessee, LLC | 90 CAPSULE in 1 BOTTLE (71610-986-60) | February 9, 2026 |
| 67877-146-01 | 67877-146 | Ascend Laboratories, LLC | 100 CAPSULE in 1 BOTTLE (67877-146-01) | April 21, 1987 |
| 67877-146-05 | 67877-146 | Ascend Laboratories, LLC | 500 CAPSULE in 1 BOTTLE (67877-146-05) | April 21, 1987 |
| 67877-147-01 | 67877-147 | Ascend Laboratories, LLC | 100 CAPSULE in 1 BOTTLE (67877-147-01) | April 21, 1987 |
| 67877-147-05 | 67877-147 | Ascend Laboratories, LLC | 500 CAPSULE in 1 BOTTLE (67877-147-05) | April 21, 1987 |
| 67877-148-01 | 67877-148 | Ascend Laboratories, LLC | 100 CAPSULE in 1 BOTTLE (67877-148-01) | June 28, 2012 |
| 67877-148-05 | 67877-148 | Ascend Laboratories, LLC | 500 CAPSULE in 1 BOTTLE (67877-148-05) | June 28, 2012 |
| 67877-148-30 | 67877-148 | Ascend Laboratories, LLC | 30 CAPSULE in 1 BOTTLE (67877-148-30) | June 28, 2012 |
| 67877-149-01 | 67877-149 | Ascend Laboratories, LLC | 100 CAPSULE in 1 BOTTLE (67877-149-01) | June 28, 2012 |
| 67877-149-05 | 67877-149 | Ascend Laboratories, LLC | 500 CAPSULE in 1 BOTTLE (67877-149-05) | June 28, 2012 |
| 67877-149-30 | 67877-149 | Ascend Laboratories, LLC | 30 CAPSULE in 1 BOTTLE (67877-149-30) | June 28, 2012 |
| 76420-472-01 | 76420-472 | Asclemed USA, Inc. | 100 CAPSULE in 1 BOTTLE (76420-472-01) | September 18, 2025 |
| 76420-472-05 | 76420-472 | Asclemed USA, Inc. | 500 CAPSULE in 1 BOTTLE (76420-472-05) | September 18, 2025 |
| 76420-472-30 | 76420-472 | Asclemed USA, Inc. | 30 CAPSULE in 1 BOTTLE (76420-472-30) | September 18, 2025 |
| 76420-472-60 | 76420-472 | Asclemed USA, Inc. | 60 CAPSULE in 1 BOTTLE (76420-472-60) | September 18, 2025 |
| 76420-472-90 | 76420-472 | Asclemed USA, Inc. | 90 CAPSULE in 1 BOTTLE (76420-472-90) | September 18, 2025 |
| 76420-473-01 | 76420-473 | Asclemed USA, Inc. | 100 CAPSULE in 1 BOTTLE (76420-473-01) | September 18, 2025 |
| 76420-473-05 | 76420-473 | Asclemed USA, Inc. | 500 CAPSULE in 1 BOTTLE (76420-473-05) | September 18, 2025 |
| 76420-473-30 | 76420-473 | Asclemed USA, Inc. | 30 CAPSULE in 1 BOTTLE (76420-473-30) | September 18, 2025 |
| 76420-473-60 | 76420-473 | Asclemed USA, Inc. | 60 CAPSULE in 1 BOTTLE (76420-473-60) | September 18, 2025 |
| 76420-473-90 | 76420-473 | Asclemed USA, Inc. | 90 CAPSULE in 1 BOTTLE (76420-473-90) | September 18, 2025 |
| 76420-474-01 | 76420-474 | Asclemed USA, Inc. | 100 CAPSULE in 1 BOTTLE (76420-474-01) | September 18, 2025 |
| 76420-474-05 | 76420-474 | Asclemed USA, Inc. | 500 CAPSULE in 1 BOTTLE (76420-474-05) | September 18, 2025 |
| 76420-474-30 | 76420-474 | Asclemed USA, Inc. | 30 CAPSULE in 1 BOTTLE (76420-474-30) | September 18, 2025 |
| 76420-474-60 | 76420-474 | Asclemed USA, Inc. | 60 CAPSULE in 1 BOTTLE (76420-474-60) | September 18, 2025 |
| 76420-474-90 | 76420-474 | Asclemed USA, Inc. | 90 CAPSULE in 1 BOTTLE (76420-474-90) | September 18, 2025 |
| 76420-475-01 | 76420-475 | Asclemed USA, Inc. | 100 CAPSULE in 1 BOTTLE (76420-475-01) | September 18, 2025 |
| 76420-475-05 | 76420-475 | Asclemed USA, Inc. | 500 CAPSULE in 1 BOTTLE (76420-475-05) | September 18, 2025 |
| 76420-475-30 | 76420-475 | Asclemed USA, Inc. | 30 CAPSULE in 1 BOTTLE (76420-475-30) | September 18, 2025 |
| 76420-475-60 | 76420-475 | Asclemed USA, Inc. | 60 CAPSULE in 1 BOTTLE (76420-475-60) | September 18, 2025 |
| 76420-475-90 | 76420-475 | Asclemed USA, Inc. | 90 CAPSULE in 1 BOTTLE (76420-475-90) | September 18, 2025 |
| 50268-779-15 | 50268-779 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-779-15) / 1 CAPSULE in 1 BLISTER PACK (50268-779-11) | October 19, 2023 |
| 50268-780-13 | 50268-780 | AvPAK | 30 BLISTER PACK in 1 BOX (50268-780-13) / 1 CAPSULE in 1 BLISTER PACK (50268-780-11) | October 19, 2023 |
| 63629-1057-1 | 63629-1057 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (63629-1057-1) | December 21, 2021 |
| 63629-1619-1 | 63629-1619 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (63629-1619-1) | June 11, 2010 |
| 63629-1619-2 | 63629-1619 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (63629-1619-2) | October 10, 2006 |
| 63629-1619-3 | 63629-1619 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (63629-1619-3) | July 28, 2006 |
| 63629-1619-4 | 63629-1619 | Bryant Ranch Prepack | 90 CAPSULE in 1 BOTTLE (63629-1619-4) | September 15, 2008 |
| 63629-1619-5 | 63629-1619 | Bryant Ranch Prepack | 28 CAPSULE in 1 BOTTLE (63629-1619-5) | April 29, 2010 |
| 63629-1619-6 | 63629-1619 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (63629-1619-6) | September 9, 2026 |
| 63629-1619-7 | 63629-1619 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (63629-1619-7) | September 9, 2026 |
| 63629-1621-1 | 63629-1621 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (63629-1621-1) | October 18, 2005 |
| 63629-1621-2 | 63629-1621 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (63629-1621-2) | October 3, 2019 |
| 63629-1621-3 | 63629-1621 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (63629-1621-3) | April 22, 2010 |
| 63629-1621-4 | 63629-1621 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (63629-1621-4) | July 18, 2006 |
| 63629-1621-5 | 63629-1621 | Bryant Ranch Prepack | 90 CAPSULE in 1 BOTTLE (63629-1621-5) | January 15, 2013 |
| 63629-1621-6 | 63629-1621 | Bryant Ranch Prepack | 28 CAPSULE in 1 BOTTLE (63629-1621-6) | March 22, 2010 |
| 63629-1621-7 | 63629-1621 | Bryant Ranch Prepack | 10 CAPSULE in 1 BOTTLE (63629-1621-7) | September 9, 2026 |
| 63629-1621-8 | 63629-1621 | Bryant Ranch Prepack | 45 CAPSULE in 1 BOTTLE (63629-1621-8) | September 9, 2026 |
| 63629-1621-9 | 63629-1621 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (63629-1621-9) | September 9, 2026 |
| 63629-8601-1 | 63629-8601 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (63629-8601-1) | July 13, 2021 |
| 63629-8602-1 | 63629-8602 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (63629-8602-1) | July 13, 2021 |
| 63629-8603-1 | 63629-8603 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (63629-8603-1) | July 13, 2021 |
| 63629-8604-1 | 63629-8604 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (63629-8604-1) | July 13, 2021 |
| 63629-8605-1 | 63629-8605 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (63629-8605-1) | July 13, 2021 |
| 63629-8606-1 | 63629-8606 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (63629-8606-1) | July 13, 2021 |
| 71335-0315-1 | 71335-0315 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (71335-0315-1) | June 21, 2018 |
| 71335-0315-2 | 71335-0315 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (71335-0315-2) | March 6, 2018 |
| 71335-0315-3 | 71335-0315 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (71335-0315-3) | February 19, 2018 |
| 71335-0315-4 | 71335-0315 | Bryant Ranch Prepack | 90 CAPSULE in 1 BOTTLE (71335-0315-4) | April 20, 2018 |
| 71335-0315-5 | 71335-0315 | Bryant Ranch Prepack | 28 CAPSULE in 1 BOTTLE (71335-0315-5) | December 27, 2021 |
| 71335-0315-6 | 71335-0315 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (71335-0315-6) | December 27, 2021 |
| 71335-0315-7 | 71335-0315 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (71335-0315-7) | December 27, 2021 |
| 71335-1901-1 | 71335-1901 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (71335-1901-1) | July 15, 2021 |
| 71335-1901-2 | 71335-1901 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (71335-1901-2) | December 11, 2024 |
| 71335-1901-3 | 71335-1901 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (71335-1901-3) | December 11, 2024 |
| 71335-1901-4 | 71335-1901 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (71335-1901-4) | August 26, 2021 |
| 71335-1901-5 | 71335-1901 | Bryant Ranch Prepack | 90 CAPSULE in 1 BOTTLE (71335-1901-5) | November 3, 2021 |
| 71335-1901-6 | 71335-1901 | Bryant Ranch Prepack | 28 CAPSULE in 1 BOTTLE (71335-1901-6) | December 11, 2024 |
| 71335-1901-7 | 71335-1901 | Bryant Ranch Prepack | 10 CAPSULE in 1 BOTTLE (71335-1901-7) | December 11, 2024 |
| 71335-1901-8 | 71335-1901 | Bryant Ranch Prepack | 45 CAPSULE in 1 BOTTLE (71335-1901-8) | December 11, 2024 |
| 71335-1901-9 | 71335-1901 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (71335-1901-9) | December 11, 2024 |
| 71335-2043-1 | 71335-2043 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (71335-2043-1) | February 10, 2022 |
| 71335-2302-1 | 71335-2302 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (71335-2302-1) | December 1, 2023 |
| 71335-2900-1 | 71335-2900 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (71335-2900-1) | November 6, 2025 |
| 71335-2910-1 | 71335-2910 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (71335-2910-1) | November 6, 2025 |
| 71335-2965-1 | 71335-2965 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (71335-2965-1) | November 6, 2025 |
| 71335-9741-1 | 71335-9741 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (71335-9741-1) | July 10, 2023 |
| 71335-9741-2 | 71335-9741 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (71335-9741-2) | July 10, 2023 |
| 71335-9741-3 | 71335-9741 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (71335-9741-3) | July 10, 2023 |
| 71335-9741-4 | 71335-9741 | Bryant Ranch Prepack | 90 CAPSULE in 1 BOTTLE (71335-9741-4) | July 10, 2023 |
| 71335-9741-5 | 71335-9741 | Bryant Ranch Prepack | 28 CAPSULE in 1 BOTTLE (71335-9741-5) | July 10, 2023 |
| 71335-9741-6 | 71335-9741 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (71335-9741-6) | July 10, 2023 |
| 71335-9741-7 | 71335-9741 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (71335-9741-7) | July 10, 2023 |
| 72162-1824-1 | 72162-1824 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (72162-1824-1) | March 7, 2024 |
| 72162-1824-5 | 72162-1824 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (72162-1824-5) | March 7, 2024 |
| 72162-1825-1 | 72162-1825 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (72162-1825-1) | January 11, 2024 |
| 72162-1825-5 | 72162-1825 | Bryant Ranch Prepack | 500 CAPSULE in 1 BOTTLE (72162-1825-5) | January 11, 2024 |
| 72162-1826-1 | 72162-1826 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (72162-1826-1) | March 6, 2024 |
| 72162-1827-3 | 72162-1827 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (72162-1827-3) | March 7, 2024 |
| 51407-507-05 | 51407-507 | Golden State Medical Supply, Inc. | 500 CAPSULE in 1 BOTTLE (51407-507-05) | June 5, 2024 |
| 51407-508-05 | 51407-508 | Golden State Medical Supply, Inc. | 500 CAPSULE in 1 BOTTLE (51407-508-05) | June 5, 2024 |
| 0904-6436-04 | 0904-6436 | Major Pharmaceuticals | 30 BLISTER PACK in 1 CARTON (0904-6436-04) / 1 CAPSULE in 1 BLISTER PACK | March 25, 2015 |
| 66267-321-30 | 66267-321 | NuCare Pharmaceuticals,Inc. | 30 CAPSULE in 1 BOTTLE (66267-321-30) | January 17, 2018 |
| 68071-4083-3 | 68071-4083 | NuCare Pharmaceuticals,Inc. | 30 CAPSULE in 1 BOTTLE (68071-4083-3) | December 29, 2017 |
| 55289-196-01 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 100 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-01) | February 5, 2016 |
| 55289-196-14 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 14 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-14) | February 5, 2016 |
| 55289-196-30 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 30 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-30) | February 5, 2016 |
| 55289-196-60 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 60 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-60) | February 5, 2016 |
| 55289-196-82 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 500 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-82) | April 20, 2020 |
| 55289-196-90 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | 90 CAPSULE in 1 BOTTLE, PLASTIC (55289-196-90) | December 13, 2018 |
| 55289-660-01 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | 100 CAPSULE in 1 BOTTLE, PLASTIC (55289-660-01) | January 21, 2016 |
| 55289-660-30 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | 30 CAPSULE in 1 BOTTLE, PLASTIC (55289-660-30) | January 21, 2016 |
| 55289-660-60 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | 60 CAPSULE in 1 BOTTLE, PLASTIC (55289-660-60) | January 21, 2016 |
| 55289-660-82 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | 500 CAPSULE in 1 BOTTLE, PLASTIC (55289-660-82) | April 20, 2020 |
| 55289-660-90 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | 90 CAPSULE in 1 BOTTLE, PLASTIC (55289-660-90) | January 21, 2016 |
| 72789-449-30 | 72789-449 | PD-Rx Pharmaceuticals, Inc. | 30 CAPSULE in 1 BOTTLE, PLASTIC (72789-449-30) | November 6, 2024 |
| 68788-8081-3 | 68788-8081 | Preferred Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (68788-8081-3) | October 5, 2021 |
| 68788-8139-3 | 68788-8139 | Preferred Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (68788-8139-3) | February 11, 2022 |
| 68788-8493-3 | 68788-8493 | Preferred Pharmaceuticals Inc. | 30 CAPSULE in 1 BOTTLE (68788-8493-3) | July 24, 2023 |
| 63187-132-30 | 63187-132 | Proficient Rx LP | 30 CAPSULE in 1 BOTTLE (63187-132-30) | January 1, 2019 |
| 63187-132-60 | 63187-132 | Proficient Rx LP | 60 CAPSULE in 1 BOTTLE (63187-132-60) | June 8, 2023 |
| 63187-132-90 | 63187-132 | Proficient Rx LP | 90 CAPSULE in 1 BOTTLE (63187-132-90) | June 8, 2023 |
| 63187-497-00 | 63187-497 | Proficient Rx LP | 100 CAPSULE in 1 BOTTLE (63187-497-00) | January 1, 2019 |
| 63187-497-30 | 63187-497 | Proficient Rx LP | 30 CAPSULE in 1 BOTTLE (63187-497-30) | January 1, 2019 |
| 63187-497-60 | 63187-497 | Proficient Rx LP | 60 CAPSULE in 1 BOTTLE (63187-497-60) | January 1, 2019 |
| 63187-497-90 | 63187-497 | Proficient Rx LP | 90 CAPSULE in 1 BOTTLE (63187-497-90) | January 1, 2019 |
| 71205-914-00 | 71205-914 | Proficient Rx LP | 100 CAPSULE in 1 BOTTLE (71205-914-00) | July 14, 2021 |
| 71205-914-30 | 71205-914 | Proficient Rx LP | 30 CAPSULE in 1 BOTTLE (71205-914-30) | July 14, 2021 |
| 71205-914-55 | 71205-914 | Proficient Rx LP | 500 CAPSULE in 1 BOTTLE (71205-914-55) | July 14, 2021 |
| 71205-914-60 | 71205-914 | Proficient Rx LP | 60 CAPSULE in 1 BOTTLE (71205-914-60) | July 14, 2021 |
| 71205-914-72 | 71205-914 | Proficient Rx LP | 120 CAPSULE in 1 BOTTLE (71205-914-72) | July 14, 2021 |
| 71205-914-90 | 71205-914 | Proficient Rx LP | 90 CAPSULE in 1 BOTTLE (71205-914-90) | July 14, 2021 |
| 71205-915-00 | 71205-915 | Proficient Rx LP | 100 CAPSULE in 1 BOTTLE (71205-915-00) | July 14, 2021 |
| 71205-915-30 | 71205-915 | Proficient Rx LP | 30 CAPSULE in 1 BOTTLE (71205-915-30) | July 14, 2021 |
| 71205-915-55 | 71205-915 | Proficient Rx LP | 500 CAPSULE in 1 BOTTLE (71205-915-55) | July 14, 2021 |
| 71205-915-60 | 71205-915 | Proficient Rx LP | 60 CAPSULE in 1 BOTTLE (71205-915-60) | July 14, 2021 |
| 71205-915-72 | 71205-915 | Proficient Rx LP | 120 CAPSULE in 1 BOTTLE (71205-915-72) | July 14, 2021 |
| 71205-915-90 | 71205-915 | Proficient Rx LP | 90 CAPSULE in 1 BOTTLE (71205-915-90) | July 14, 2021 |
| 70518-0647-0 | 70518-0647 | REMEDYREPACK INC. | 30 CAPSULE in 1 BLISTER PACK (70518-0647-0) | July 28, 2017 |
| 70518-2487-2 | 70518-2487 | REMEDYREPACK INC. | 30 CAPSULE in 1 BLISTER PACK (70518-2487-2) | August 13, 2025 |
| 43547-611-10 | 43547-611 | Solco Healthcare U.S., LLC | 100 CAPSULE in 1 BOTTLE, PLASTIC (43547-611-10) | January 5, 2023 |
| 43547-612-10 | 43547-612 | Solco Healthcare U.S., LLC | 100 CAPSULE in 1 BOTTLE, PLASTIC (43547-612-10) | January 5, 2023 |
| 43547-612-50 | 43547-612 | Solco Healthcare U.S., LLC | 500 CAPSULE in 1 BOTTLE, PLASTIC (43547-612-50) | January 5, 2023 |
| 43547-613-03 | 43547-613 | Solco Healthcare U.S., LLC | 30 CAPSULE in 1 BOTTLE, PLASTIC (43547-613-03) | January 5, 2023 |
| 43547-614-10 | 43547-614 | Solco Healthcare U.S., LLC | 100 CAPSULE in 1 BOTTLE, PLASTIC (43547-614-10) | January 5, 2023 |
| 43547-614-50 | 43547-614 | Solco Healthcare U.S., LLC | 500 CAPSULE in 1 BOTTLE, PLASTIC (43547-614-50) | January 5, 2023 |
| 0406-9959-03 | 0406-9959 | SpecGx LLC | 30 CAPSULE in 1 BOTTLE (0406-9959-03) | February 23, 2010 |
| 0406-9960-01 | 0406-9960 | SpecGx LLC | 100 CAPSULE in 1 BOTTLE (0406-9960-01) | February 23, 2010 |
| 0406-9961-01 | 0406-9961 | SpecGx LLC | 100 CAPSULE in 1 BOTTLE (0406-9961-01) | February 23, 2010 |
| 0406-9962-01 | 0406-9962 | SpecGx LLC | 100 CAPSULE in 1 BOTTLE (0406-9962-01) | February 23, 2010 |
| 50090-0186 | 50090-0186 | A-S Medication Solutions | — | April 21, 1987 |
| 50090-0285 | 50090-0285 | A-S Medication Solutions | — | April 21, 1987 |
| 0228-2076 | 0228-2076 | Actavis Pharma, Inc. | — | September 30, 1990 |
| 0228-2077 | 0228-2077 | Actavis Pharma, Inc. | — | September 30, 1990 |
| 80425-0191 | 80425-0191 | Advanced Rx Pharmacy of Tennessee, LLC | — | June 14, 2022 |
| 80425-0295 | 80425-0295 | Advanced Rx Pharmacy of Tennessee, LLC | — | April 4, 2023 |
| 62332-379 | 62332-379 | Alembic Pharmaceuticals Inc. | — | November 27, 2018 |
| 62332-380 | 62332-380 | Alembic Pharmaceuticals Inc. | — | November 27, 2018 |
| 62332-381 | 62332-381 | Alembic Pharmaceuticals Inc. | — | November 27, 2018 |
| 62332-382 | 62332-382 | Alembic Pharmaceuticals Inc. | — | November 27, 2018 |
| 46708-379 | 46708-379 | Alembic Pharmaceuticals Limited | — | November 27, 2018 |
| 46708-380 | 46708-380 | Alembic Pharmaceuticals Limited | — | November 27, 2018 |
| 46708-381 | 46708-381 | Alembic Pharmaceuticals Limited | — | November 27, 2018 |
| 46708-382 | 46708-382 | Alembic Pharmaceuticals Limited | — | November 27, 2018 |
| 68084-549 | 68084-549 | American Health Packaging | — | August 1, 2012 |
| 65162-556 | 65162-556 | Amneal Pharmaceuticals LLC | — | May 23, 2016 |
| 65162-557 | 65162-557 | Amneal Pharmaceuticals LLC | — | May 23, 2016 |
| 65162-583 | 65162-583 | Amneal Pharmaceuticals LLC | — | May 23, 2016 |
| 65162-584 | 65162-584 | Amneal Pharmaceuticals LLC | — | May 23, 2016 |
| 53746-556 | 53746-556 | Amneal Pharmaceuticals of New York LLC | — | February 19, 2024 |
| 53746-557 | 53746-557 | Amneal Pharmaceuticals of New York LLC | — | February 19, 2024 |
| 43353-260 | 43353-260 | Aphena Pharma Solutions - Tennessee, LLC | — | April 21, 1987 |
| 43353-312 | 43353-312 | Aphena Pharma Solutions - Tennessee, LLC | — | April 21, 1987 |
| 67544-136 | 67544-136 | Aphena Pharma Solutions - Tennessee, LLC | — | August 3, 1987 |
| 71610-004 | 71610-004 | Aphena Pharma Solutions - Tennessee, LLC | — | February 23, 2010 |
| 71610-625 | 71610-625 | Aphena Pharma Solutions - Tennessee, LLC | — | February 23, 2010 |
| 71610-626 | 71610-626 | Aphena Pharma Solutions - Tennessee, LLC | — | February 23, 2010 |
| 71610-986 | 71610-986 | Aphena Pharma Solutions - Tennessee, LLC | — | November 23, 2018 |
| 67877-146 | 67877-146 | Ascend Laboratories, LLC | — | April 21, 1987 |
| 67877-147 | 67877-147 | Ascend Laboratories, LLC | — | April 21, 1987 |
| 67877-148 | 67877-148 | Ascend Laboratories, LLC | — | June 28, 2012 |
| 67877-149 | 67877-149 | Ascend Laboratories, LLC | — | June 28, 2012 |
| 76420-472 | 76420-472 | Asclemed USA, Inc. | — | June 28, 2012 |
| 76420-473 | 76420-473 | Asclemed USA, Inc. | — | April 21, 1987 |
| 76420-474 | 76420-474 | Asclemed USA, Inc. | — | June 28, 2012 |
| 76420-475 | 76420-475 | Asclemed USA, Inc. | — | April 21, 1987 |
| 50268-779 | 50268-779 | AvPAK | — | October 19, 2023 |
| 50268-780 | 50268-780 | AvPAK | — | October 19, 2023 |
| 63629-1057 | 63629-1057 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-1619 | 63629-1619 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-1621 | 63629-1621 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-8601 | 63629-8601 | Bryant Ranch Prepack | — | June 28, 2012 |
| 63629-8602 | 63629-8602 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-8603 | 63629-8603 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-8604 | 63629-8604 | Bryant Ranch Prepack | — | June 28, 2012 |
| 63629-8605 | 63629-8605 | Bryant Ranch Prepack | — | April 21, 1987 |
| 63629-8606 | 63629-8606 | Bryant Ranch Prepack | — | April 21, 1987 |
| 71335-0315 | 71335-0315 | Bryant Ranch Prepack | — | September 30, 1990 |
| 71335-1901 | 71335-1901 | Bryant Ranch Prepack | — | May 23, 2016 |
| 71335-2043 | 71335-2043 | Bryant Ranch Prepack | — | November 27, 2018 |
| 71335-2302 | 71335-2302 | Bryant Ranch Prepack | — | April 21, 1987 |
| 71335-2900 | 71335-2900 | Bryant Ranch Prepack | — | April 21, 1987 |
| 71335-2910 | 71335-2910 | Bryant Ranch Prepack | — | April 21, 1987 |
| 71335-2965 | 71335-2965 | Bryant Ranch Prepack | — | April 21, 1987 |
| 71335-9741 | 71335-9741 | Bryant Ranch Prepack | — | November 27, 2018 |
| 72162-1824 | 72162-1824 | Bryant Ranch Prepack | — | April 21, 1987 |
| 72162-1825 | 72162-1825 | Bryant Ranch Prepack | — | April 21, 1987 |
| 72162-1826 | 72162-1826 | Bryant Ranch Prepack | — | June 28, 2012 |
| 72162-1827 | 72162-1827 | Bryant Ranch Prepack | — | June 28, 2012 |
| 51407-507 | 51407-507 | Golden State Medical Supply, Inc. | — | November 23, 2018 |
| 51407-508 | 51407-508 | Golden State Medical Supply, Inc. | — | November 23, 2018 |
| 0904-6436 | 0904-6436 | Major Pharmaceuticals | — | March 25, 2015 |
| 66267-321 | 66267-321 | NuCare Pharmaceuticals,Inc. | — | April 21, 1987 |
| 68071-4083 | 68071-4083 | NuCare Pharmaceuticals,Inc. | — | September 30, 1990 |
| 55289-196 | 55289-196 | PD-Rx Pharmaceuticals, Inc. | — | April 21, 1987 |
| 55289-660 | 55289-660 | PD-Rx Pharmaceuticals, Inc. | — | April 21, 1987 |
| 72789-449 | 72789-449 | PD-Rx Pharmaceuticals, Inc. | — | February 23, 2010 |
| 68788-8081 | 68788-8081 | Preferred Pharmaceuticals Inc. | — | October 5, 2021 |
| 68788-8139 | 68788-8139 | Preferred Pharmaceuticals Inc. | — | February 11, 2022 |
| 68788-8493 | 68788-8493 | Preferred Pharmaceuticals Inc. | — | July 24, 2023 |
| 63187-132 | 63187-132 | Proficient Rx LP | — | April 21, 1987 |
| 63187-497 | 63187-497 | Proficient Rx LP | — | April 21, 1987 |
| 71205-914 | 71205-914 | Proficient Rx LP | — | April 21, 1987 |
| 71205-915 | 71205-915 | Proficient Rx LP | — | April 21, 1987 |
| 70518-0647 | 70518-0647 | REMEDYREPACK INC. | — | July 28, 2017 |
| 70518-2487 | 70518-2487 | REMEDYREPACK INC. | — | December 16, 2019 |
| 43547-611 | 43547-611 | Solco Healthcare U.S., LLC | — | January 5, 2023 |
| 43547-612 | 43547-612 | Solco Healthcare U.S., LLC | — | January 5, 2023 |
| 43547-613 | 43547-613 | Solco Healthcare U.S., LLC | — | January 5, 2023 |
| 43547-614 | 43547-614 | Solco Healthcare U.S., LLC | — | January 5, 2023 |
| 0406-9959 | 0406-9959 | SpecGx LLC | — | February 23, 2010 |
| 0406-9960 | 0406-9960 | SpecGx LLC | — | February 23, 2010 |
| 0406-9961 | 0406-9961 | SpecGx LLC | — | February 23, 2010 |
| 0406-9962 | 0406-9962 | SpecGx LLC | — | February 23, 2010 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.